Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paritaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paritaprevir SCHEMBL25744892 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL29359149 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3061958 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3061962 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3069969 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL18713503 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL16541443 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL18923192 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL19286688 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL20145316 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | claimed |
| EP-2544689-B1 | SOLID COMPOSITIONS | ABBVIE BAHAMAS LTD (BS) | 2017-01-11 | — | — | EP | claimed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | claimed |
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-29 | — | — | US | claimed |
| EP-2468286-B1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2014-04-23 | — | — | EP | claimed |
| EP-2468287-B1 | Macrocyclic hepatitis c serine protease inhibitors | ENANTA PHARM INC (US) | 2014-04-23 | — | — | EP | claimed |
| EP-2340029-B1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2014-03-05 | — | — | EP | claimed |
| US-8420596-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | claimed |
| US-20120196792-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | claimed |
| EP-2468286-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | claimed |
| EP-2468285-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | claimed |
| US-20110312973-A1 | SOLID COMPOSITIONS | ABBVIE INC. | 2011-12-22 | — | — | US | claimed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | claimed |
| US-20240232171-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240115650-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230385268-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| EP-2468286-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468287-A1 | Macrocyclic hepatitis c serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110312973-A1 | SOLID COMPOSITIONS | ABBVIE INC. | 2011-12-22 | — | — | US | disclosed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | CTSB 65/4885ADRB3 3933/4885ADRA2B 4558/4885 |
| US-20120196792-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | CTSB 65/4885ADRB3 3933/4885ADRA2B 4558/4885 |
| US-20240115650-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | CTSB 394/4885ADRB3 2147/4885ADRA2B 1384/4885 |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | TMPRSS15, PRSS1, SPINT2 | CTSB 65/4885ADRB3 3933/4885ADRA2B 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.